Shandong Buchang Pharmaceuticals Valuation
Is 603858 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 603858 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 603858 (CN¥15.15) is trading above our estimate of fair value (CN¥2.8)
Significantly Below Fair Value: 603858 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 603858?
Other financial metrics that can be useful for relative valuation.
What is 603858's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CN¥16.60b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.5x |
Enterprise Value/EBITDA | 16.4x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 603858's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 3.1x | ||
002019 Yifan Pharmaceutical | 3.4x | 17.9% | CN¥15.0b |
600867 Tonghua Dongbao Pharmaceutical | 5.5x | 12.3% | CN¥16.5b |
600420 Shanghai Shyndec Pharmaceutical | 1.2x | 12.4% | CN¥14.1b |
600535 Tasly Pharmaceutical Group | 2.2x | 6.4% | CN¥18.8b |
603858 Shandong Buchang Pharmaceuticals | 1.3x | n/a | CN¥16.6b |
Price-To-Sales vs Peers: 603858 is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (3.1x).
Price to Earnings Ratio vs Industry
How does 603858's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?
Price-To-Sales vs Industry: 603858 is good value based on its Price-To-Sales Ratio (1.3x) compared to the CN Pharmaceuticals industry average (2.9x).
Price to Sales Ratio vs Fair Ratio
What is 603858's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 1.3x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 603858's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.